CLINICAL TRIALS PROFILE FOR ZEPOSIA
✉ Email this page to a colleague
All Clinical Trials for ZEPOSIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05777902 ↗ | Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis. | Recruiting | I.R.C.C.S. Fondazione Santa Lucia | Phase 4 | 2023-01-31 | This is a prospective interventional study with a 12-month follow-up of patients diagnosed with Multiple Sclerosis. Enrollment includes patients for whom Ozanimod will be prescribed based on regular clinical practice. It is proposed to integrate the measurements obtained using multiple instruments, with the aim of analyzing the immunological landscape, connectivity networks and anatomical traits of neurodegeneration. Patients will return for imaging and noninvasive electrophysiological studies 3, 6, and 12 months after initiation of therapy. On the same day, blood samples will be taken and immunological and biochemical tests will be performed. |
| NCT06188637 ↗ | Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study | Not yet recruiting | Bristol-Myers Squibb | Phase 4 | 2024-03-01 | The ULTRAZ study is designed to better understand the mode of action of S1P receptor modulators. The alteration of leukocyte trafficking due to S1P receptors such as ozanimod is mainly investigated in rodent studies. Several previous studies show a reduced total leukocyte count in peripheral blood and only two study reported the effect of leukocyte subgroups before and after treatment with ozanimod. The change in leukocyte subgroups in peripheral blood as well as colonic mucosa and lymph nodes have not been investigated to our knowledge. Therefore, the aim of this study is to explore the changes in these three compartments. |
| NCT06188637 ↗ | Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study | Not yet recruiting | Geert D'Haens | Phase 4 | 2024-03-01 | The ULTRAZ study is designed to better understand the mode of action of S1P receptor modulators. The alteration of leukocyte trafficking due to S1P receptors such as ozanimod is mainly investigated in rodent studies. Several previous studies show a reduced total leukocyte count in peripheral blood and only two study reported the effect of leukocyte subgroups before and after treatment with ozanimod. The change in leukocyte subgroups in peripheral blood as well as colonic mucosa and lymph nodes have not been investigated to our knowledge. Therefore, the aim of this study is to explore the changes in these three compartments. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZEPOSIA
Condition Name
Clinical Trial Locations for ZEPOSIA
Clinical Trial Progress for ZEPOSIA
Clinical Trial Phase
Clinical Trial Sponsors for ZEPOSIA
Sponsor Name
